__timestamp | Blueprint Medicines Corporation | Novo Nordisk A/S |
---|---|---|
Wednesday, January 1, 2014 | 7890000 | 26760000000 |
Thursday, January 1, 2015 | 14456000 | 32169000000 |
Friday, January 1, 2016 | 19218000 | 32339000000 |
Sunday, January 1, 2017 | 27986000 | 32124000000 |
Monday, January 1, 2018 | 47928000 | 33313000000 |
Tuesday, January 1, 2019 | 96388000 | 35830000000 |
Wednesday, January 1, 2020 | 157743000 | 36886000000 |
Friday, January 1, 2021 | 195293000 | 41058000000 |
Saturday, January 1, 2022 | 237374000 | 50684000000 |
Sunday, January 1, 2023 | 295141000 | 61598000000 |
Monday, January 1, 2024 | 359272000 | 67377000000 |
Cracking the code
In the ever-evolving landscape of the pharmaceutical industry, effective cost management is crucial. This chart provides a fascinating insight into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Novo Nordisk A/S and Blueprint Medicines Corporation, from 2014 to 2023.
Novo Nordisk, a global leader in diabetes care, has consistently maintained a robust SG&A expense profile, with a notable increase of approximately 130% over the decade. In 2023, their expenses reached a peak, reflecting strategic investments in marketing and administrative capabilities.
Conversely, Blueprint Medicines, a trailblazer in precision therapy, has seen a staggering 3,600% rise in SG&A expenses, indicative of their aggressive expansion and market penetration strategies.
This comparative analysis underscores the diverse approaches to cost management in the pharmaceutical sector, highlighting the balance between growth and operational efficiency.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Johnson & Johnson
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and Madrigal Pharmaceuticals, Inc.
Novo Nordisk A/S and Walgreens Boots Alliance, Inc.: SG&A Spending Patterns Compared
Novo Nordisk A/S vs Grifols, S.A.: SG&A Expense Trends
GSK plc and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Lantheus Holdings, Inc.
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Verona Pharma plc
Blueprint Medicines Corporation vs HUTCHMED (China) Limited: SG&A Expense Trends
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs Novavax, Inc.